FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Andriy Rusyn et al.|Annals of Oncology|2021Cited by 357
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216